Hill Holliday Health launches inside its Boston-based parent agency

Hill Holliday Health launches with executive creative director David Leonardi and managing director Scott Rabschnuk at the helm. (Business Wire)

Boston ad agency Hill Holliday has been doing pharma and healthcare work for years. But not many people seemed to know about it. So last week, the agency created a health-specific branded agency within itself with the launch of Hill Holliday Health.

The agency made a conscious decision years ago to not brand as a healthcare agency in order to stand out with its consumer approach in the busy healthcare marketing arena, managing director Scott Rabschnuk explained. But more recently, Hill Holliday discovered that, especially when it came to recruiting health marketing talent, people would say they “didn’t even know you guys did healthcare."

RELATED: FCB Health launches stand-alone agency for pharma and healthcare branding

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

“We realized we weren’t on the radar, so we were having a hard time attracting talent and we probably weren’t getting our fair share of at-bats with clients,” he said. “We can still be that consumer-oriented healthcare organization and our work speaks for itself, but we need to brand ourselves and give ourselves an identity so that both prospective clients as well as great industry talent, knows we’re on the map.”

The 120-person workforce of Hill Holliday Health will continue its work for pharma clients such as Novartis and Johnson & Johnson’s Janssen for brands Xarelto and Invokana, as well as pitch for new business and look to hire more healthcare talent.

Suggested Articles

With AbbVie's two most recent launches outperforming expectations, investors could be looking at a steal with an Allergan merger looming.

Investors are clamoring for a CVR created in the BMS-Celgene deal, but it will only pay off if the FDA approves three hot pipeline projects.

Muzammil Mansuri, Sanofi’s EVP of strategy and business development since February 2016, is retiring at the end of November.